[go: up one dir, main page]

WO1999043335A1 - Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises - Google Patents

Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises Download PDF

Info

Publication number
WO1999043335A1
WO1999043335A1 PCT/AU1999/000111 AU9900111W WO9943335A1 WO 1999043335 A1 WO1999043335 A1 WO 1999043335A1 AU 9900111 W AU9900111 W AU 9900111W WO 9943335 A1 WO9943335 A1 WO 9943335A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
extract
clover
organic solvent
daidzein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU1999/000111
Other languages
English (en)
Inventor
Michael Joseph Thurn
Li Jui Huang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kazia Research Pty Ltd
Original Assignee
Novogen Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd
Priority to CA002320777A priority Critical patent/CA2320777A1/fr
Priority to EP19990908672 priority patent/EP1056463A4/fr
Priority to AU28189/99A priority patent/AU2818999A/en
Publication of WO1999043335A1 publication Critical patent/WO1999043335A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae

Definitions

  • daidzein H genistein
  • R OH the structure of biochanin is the same as for genistein but with a 4'-methoxy group, and similarly formononetin has the same structure as daidzein, but with a 4'-methoxy group.
  • Chemotherapy for the treatment of cancer is harsh, often generally being cytotoxic and affecting fast growing cells such as those of the intestinal region, and hair cells. Unpleasant side effects often include nausea, loss of taste, lethargy, hair loss, loss of libido, and the like. Anti-cancer therapeutic agents are generally costly and in some cases may only be administered by intravenous infusion.
  • Suitable carriers may be fillers, such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, and also binders, such as starch pastes using, for example, corn, wheat, rice or potato starch, gelatin, tragacanth, methylceullose and/or polyvinylpyrrolidone, and, if desired, disintegrators, such as the above-mentioned starches, also carboxymethyl starch, cross linked polyvinyl pyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate.
  • fillers such as sugars, for example lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate
  • binders such as starch pastes using,
  • compositions suitable for topical administration to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, and a combination of two or more thereof.
  • the extract is generally present at a concentration of from 0.1 % to 30% weight/weight, for example from 0.5% to 10% weight/weight.
  • the compositions of the present invention induce one or more effects of inhibition of cell proliferation, induction of cell differentiation, induction of apoptosis (programmed cell death), DNA fragmentation or cell cycle blocking which all represent anti-cancer activity.
  • the compositions of the present invention have wide ranging activity against cancer cells and are accordingly effective in the treatment, prophylaxis, amelioration, defence against and/or prevention of cancers including benign prostatic hypertrophy, prostatic cancer, breast cancer, uterine cancer, leukaemia, ovarian cancer, endometrial cancer, cervical cancer, colon (large bowel) cancer, testicular cancer, Hodgkin's disease, lymphoma, rhabdo sarcoma, neuroblastoma, pancreatic cancer, lung cancer, brain tumour, skin cancer, stomach (gastric) cancer, oral cancer, liver cancer, laryngeal cancer, bladder cancer, thyroid cancer, and nasopharyngeal carcinoma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Composition constituées d'un extrait de trèfle à base d'eau/solvant organique, duquel on a enlevé les composés contenant le chromophore aromatique, comprenant des isoflavones, telles que la génistéine, la daidzénine, la formononétine et la biochanine et/ou leurs glycosides. Ledit extrait a une activité anti-cancéreuse contre une ou plusieurs des lignées cellulaires HLK60, K562, LNCaP ou HT29, éventuellement en association avec un ou plusieurs, excipients, auxiliaires et/ou diluants et vecteurs pharmaceutiquement acceptables. L'invention concerne aussi des procédés de production desdites compositions, des méthodes de traitement, d'atténuation du cancer, de prophylaxie ou de défense contre le cancer.
PCT/AU1999/000111 1998-02-25 1999-02-25 Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises Ceased WO1999043335A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002320777A CA2320777A1 (fr) 1998-02-25 1999-02-25 Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises
EP19990908672 EP1056463A4 (fr) 1998-02-25 1999-02-25 Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises
AU28189/99A AU2818999A (en) 1998-02-25 1999-02-25 Plant extracts and anti-cancer modalities involving the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP1987 1998-02-25
AUPP1987A AUPP198798A0 (en) 1998-02-25 1998-02-25 Compositions comprising extracts of isoflavone-containing plants and anti-cancer modalities involving the same

Publications (1)

Publication Number Publication Date
WO1999043335A1 true WO1999043335A1 (fr) 1999-09-02

Family

ID=3806255

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1999/000111 Ceased WO1999043335A1 (fr) 1998-02-25 1999-02-25 Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises

Country Status (4)

Country Link
EP (1) EP1056463A4 (fr)
AU (1) AUPP198798A0 (fr)
CA (1) CA2320777A1 (fr)
WO (1) WO1999043335A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1174144A1 (fr) * 2000-07-20 2002-01-23 Linnea S.A. Extrait sec riche en isoflavones et procédé de préparation
WO2002053152A1 (fr) * 2001-01-08 2002-07-11 Imperial College Of Science, Technology & Medicine Compositions contenant des flavonoides pour le traitement de troubles cerebraux
US6987098B2 (en) 1992-05-19 2006-01-17 Novogen Research Pty. Ltd. Health supplement
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
US7202273B2 (en) 1996-08-30 2007-04-10 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
WO2007073908A1 (fr) 2005-12-29 2007-07-05 Evultis S.A. Procede d’isolement de principes pharmacologiquement actifs d’origine vegetale et animale
EP1842541A1 (fr) 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Composé et extraits de plantes et leur utilisation
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
CN106153808A (zh) * 2015-03-30 2016-11-23 贵州百灵企业集团和仁堂药业有限公司 一种康妇灵胶囊的检测方法
CN113845549A (zh) * 2021-09-26 2021-12-28 广州鲁比生物科技有限公司 一种芒柄花黄素衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140805A (en) * 1977-03-11 1979-02-20 Edwards George W Process of producing useful materials from plants
GB2136812A (en) * 1983-03-23 1984-09-26 Osaka Chem Lab A method of isolating soya saponins
WO1993023069A1 (fr) * 1992-05-19 1993-11-25 Graham Edmund Kelly Complements benefiques pour la sante, contenant des phyto-×strogenes, des analogues ou des metabolites de ceux-ci
AU4003497A (en) * 1996-08-30 1998-03-19 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857325A (en) * 1985-04-24 1989-08-15 Bar-Ilan University Antioxidant compositions and methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140805A (en) * 1977-03-11 1979-02-20 Edwards George W Process of producing useful materials from plants
GB2136812A (en) * 1983-03-23 1984-09-26 Osaka Chem Lab A method of isolating soya saponins
WO1993023069A1 (fr) * 1992-05-19 1993-11-25 Graham Edmund Kelly Complements benefiques pour la sante, contenant des phyto-×strogenes, des analogues ou des metabolites de ceux-ci
AU4003497A (en) * 1996-08-30 1998-03-19 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI WORLD PATENT INF 1 January 1900 (1900-01-01), ARTYUKH M A, BATOVA R S, PETERSONE E Y U: "Surface active polysaccharide cpds. - extracted from leguminous plant leaves and stems with water and alcohol for use as emulsifiers in dr mfr.", XP002905385, Database accession no. 1982-19629E *
DATABASE WPI WORLD PATENT INF 1 January 1900 (1900-01-01), KAZAKOV A L, KOMPANTSEV V A, LYKYANOV M S: "Preparation having anti-sclerotic and cholagogic effects - by treating red clover with specific amount of ethanol in rotational extractor, then extracting cake with solvent", XP002905386, Database accession no. 1997-279357 *
PATENT ABSTRACTS OF JAPAN, (C-265), page 15; & JP 59175496 A (OOSAKA YAKUHIN KENKYUSHO KK) 4 October 1984. *
PATENT ABSTRACTS OF JAPAN, (C-442), page 66; & JP 62063581 A (COSMO CO LTD) 20 March 1987. *
PATENT ABSTRACTS OF JAPAN, (C-447), page 60; & JP 62083848 A (RIYOUSHIYOKU KENKYUKAI) 17 April 1987. *
See also references of EP1056463A4 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987098B2 (en) 1992-05-19 2006-01-17 Novogen Research Pty. Ltd. Health supplement
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
US7045155B2 (en) 1992-05-19 2006-05-16 Novogen Research Pty Ltd. Dietary supplements comprising soy hypocotyls containing at least one isoflavone
US7202273B2 (en) 1996-08-30 2007-04-10 Novogen Research Pty Ltd Therapeutic methods and compositions involving isoflavones
US7033621B1 (en) 1997-04-28 2006-04-25 Novogen, Inc. Isoflavone compositions produced from legumes
US7488494B2 (en) 1999-09-06 2009-02-10 Novogen Research Pty Ltd. Compositions and therapeutic methods involving isoflavones and analogues thereof
US6500965B2 (en) 2000-07-20 2002-12-31 Linnea Sa Dry extract which is rich in isoflavones in the form of aglycones and process for preparing the same
EP1174144A1 (fr) * 2000-07-20 2002-01-23 Linnea S.A. Extrait sec riche en isoflavones et procédé de préparation
WO2002053152A1 (fr) * 2001-01-08 2002-07-11 Imperial College Of Science, Technology & Medicine Compositions contenant des flavonoides pour le traitement de troubles cerebraux
US7312344B2 (en) 2001-03-08 2007-12-25 Novogen Research Pty Limited Dimeric isoflavones
WO2007073908A1 (fr) 2005-12-29 2007-07-05 Evultis S.A. Procede d’isolement de principes pharmacologiquement actifs d’origine vegetale et animale
EP1842541A1 (fr) 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Composé et extraits de plantes et leur utilisation
CN106153808A (zh) * 2015-03-30 2016-11-23 贵州百灵企业集团和仁堂药业有限公司 一种康妇灵胶囊的检测方法
CN113845549A (zh) * 2021-09-26 2021-12-28 广州鲁比生物科技有限公司 一种芒柄花黄素衍生物及其制备方法和应用
CN113845549B (zh) * 2021-09-26 2023-09-19 广州鲁比生物科技有限公司 一种芒柄花黄素衍生物及其制备方法和应用

Also Published As

Publication number Publication date
AUPP198798A0 (en) 1998-03-19
EP1056463A4 (fr) 2002-11-05
CA2320777A1 (fr) 1999-09-02
EP1056463A1 (fr) 2000-12-06

Similar Documents

Publication Publication Date Title
US6004558A (en) Methods for treating cancer with legume plant extracts
Falsaperla et al. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate
Landström et al. Inhibitory effects of soy and rye diets on the development of Dunning R3327 prostate adenocarcinoma in rats
KR101135824B1 (ko) 잔토세라스 소르비폴리아 추출물을 포함하는 조성물,이로부터 단리된 화합물, 이의 제조방법 및 이의 용도
US5270041A (en) Sterols, their fatty acid esters and glucosides; processes for their preparation; spontaneously dispersible agents containing these compounds, and their use for treatment of tumors
JP4880479B2 (ja) キサントセラスソルビフォリア抽出物を含む組成物、該抽出物から単離された化合物、それを調製する方法、およびその使用方法
WO1999043335A1 (fr) Extraits de plante et methodes anticancereuses dans lesquels ils sont utilises
EP1487434B1 (fr) Compositions d'extrait botanique ayant une action anticancereuse contenant du isoliquiritgenine
Ghafar et al. Regression of prostate cancer following administration of genistein combined polysaccharide (GCP™), a nutritional supplement: a case report
Deepalakshmi et al. Modulatory effect of Ganoderma lucidum on expression of xenobiotic enzymes, oxidant-antioxidant and hormonal status in 7, 12-dimethylbenz (a) anthracene-induced mammary carcinoma in rats
JP2012500776A (ja) ハナスゲａｎｅｍａｒｒｈｅｎａａｓｐｈｏｄｅｌｏｉｄｅｓｂｕｎｇｅの抽出物を使用する抗癌方法
JP2000239171A (ja) 経口ｑｏｌ改善剤
Van Der Heide et al. Flavonoids and thyroid disease
AU2818999A (en) Plant extracts and anti-cancer modalities involving the same
AU9778698A (en) A (fagopyrum cymosum) (trev.) meisn composition, method to prepare and analyze the same and uses thereof
KR102829783B1 (ko) 아이소임페라토린을 유효성분으로 포함하는 전립선 관련 질환의 예방 및 치료용 조성물
KR20030083348A (ko) 지방세포 분화 저해 활성을 가지는 프로토베르베린알칼로이드 화합물인 베르베린을 유효성분으로 함유하는비만예방 및 치료
Ogundigie et al. Effect of biochanin-a or testosterone on liver-tumors induced by a combined treatment of den and fission neutron in bcf1 mice
Babakhani et al. The Evaluation of Antioxidant and Anticancer Activity of Alfalfa Extract on MCF7 Cell Line
KR102046624B1 (ko) 칠피 추출물의 에틸아세테이트 분획물과 그 소분획물을 포함하는 항암용 조성물, 및 이의 용도
Sivalokanathan et al. Anticancer potency of Terminalia arjuna bark on N-nitrosodiethylamine-induced hepatocellular carcinoma in rats
JPS62209023A (ja) 抗アレルギ−剤
Kulwat et al. Antimutagenicity and DT-diaphorase inducing activity of Gynostemma pentaphyllum Makino extract
KR20010101065A (ko) 표고버섯 균사체 추출물 유래의 ｌａｋ 활성증강물질 및이를 함유하는 ｌａｋ 활성증강용 제제
CN111909119B (zh) 雷公藤来源化合物及其应用和制备方法、药物组合物、杀虫剂

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 28189/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2320777

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2320777

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999908672

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

WWP Wipo information: published in national office

Ref document number: 1999908672

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999908672

Country of ref document: EP